{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:09:13Z","timestamp":1779167353881,"version":"3.51.4"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-026-01634-2","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:24:52Z","timestamp":1779164692000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimising patient centred drug development to realise impact"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1856-837X","authenticated-orcid":false,"given":"Melanie","family":"Calvert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Kamudoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6715-2514","authenticated-orcid":false,"given":"Christina","family":"Yap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6043-7306","authenticated-orcid":false,"given":"Roger","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9122-8251","authenticated-orcid":false,"given":"Olalekan Lee","family":"Aiyegbusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"1634_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102228","volume":"64","author":"E Alger","year":"2023","unstructured":"Alger, E., Minchom, A., Aiyegbusi, O. L., Schipper, M. & Yap, C. Statistical methods and data visualisation of patient-reported outcomes in early phase dose-finding oncology trials: a methodological review. eClinicalMedicine 64, 102228 (2023).","journal-title":"eClinicalMedicine"},{"key":"1634_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1586\/erp.10.15","volume":"10","author":"HJ Au","year":"2010","unstructured":"Au, H. J. et al. Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Rev. Pharmacoecon Outcomes Res. 10, 119\u2013128 (2010).","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"1634_CR3","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","volume":"14","author":"IF Tannock","year":"1996","unstructured":"Tannock, I. F. et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 14, 1756\u20131764 (1996).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"1634_CR4","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/jnci\/djac128","volume":"114","author":"MD Brundage","year":"2022","unstructured":"Brundage, M. D. et al. Listening to the patient voice adds value to cancer clinical trials. JNCI: J. Natl. Cancer Inst. 114, 1323\u20131332 (2022).","journal-title":"JNCI: J. Natl. Cancer Inst."},{"key":"1634_CR5","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/jnci\/djac129","volume":"114","author":"V Bhatnagar","year":"2022","unstructured":"Bhatnagar, V. & Kluetz, P. G. Encouraging rigorous patient-generated data all along the drug development continuum. J. Natl. Cancer Inst. 114, 1313\u20131314 (2022).","journal-title":"J. Natl. Cancer Inst."},{"key":"1634_CR6","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s11136-017-1508-6","volume":"26","author":"R Mercieca-Bebber","year":"2017","unstructured":"Mercieca-Bebber, R. et al. International Society for Quality of Life Research (ISOQOL) best practice for PROs\u2014Reporting Taskforce. Preliminary evidence on the uptake, use and benefits of the CONSORT-PRO extension. Qual. Life Res. 26, 1427\u20131437 (2017).","journal-title":"Qual. Life Res."},{"key":"1634_CR7","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.jval.2025.05.002","volume":"28","author":"M Krol","year":"2025","unstructured":"Krol, M. et al. The increasing use of clinical outcome assessments in US Food and Drug Administration Labels and the German Gemeinsamer Bundesausschuss, National Institute for Health and Care Excellence, and the French Haute Autorit\u00e9 de Sant\u00e9 Assessments From 2012 to 2022. Value Health 28, 1195\u20131203 (2025).","journal-title":"Value Health"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01634-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01634-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01634-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:24:52Z","timestamp":1779164692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01634-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":7,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1634"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01634-2","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MJC received personal fees from Astellas, Boehringer Ingelheim, Aparito Ltd, CIS Oncology, Gilead, Halfloop, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK, Pfizer, Vertex, Shionogi, and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. In addition, a family member owns shares in GSK. C.Y. report personal fees from Faron Pharmaceuticals, Bayer, Trogenix and Merck, outside the submitted work. C.S. currently receives personal consulting fees from Movember and Pfizer and previously received personal consulting fees from Shionogi. Dr. Snyder has received travel costs for meeting presentations from Shionogi and Executive Insight Healthcare Consultants. She also receives research funding from Johnson & Johnson through her institution. O.L.A. declares personal fees from Gilead Sciences, Merck, Boehringer Ingelheim, Innovate UK, and GSK. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"285"}}